NCT03744715 2024-03-05A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibSpectrum Pharmaceuticals, IncPhase 2 Terminated7 enrolled
NCT03429101 2021-01-15A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerSpectrum Pharmaceuticals, IncPhase 1 Terminated6 enrolled